Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistent Readiness Through Early Prediction Immunization Study
NCT05346302Phase 1Completed
- Sponsor
- Texas A&M University
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 23-valent pneumococcal polysaccharide vaccine and salmonella typhi capsular polysaccharide vaccine (3 arms), sponsored by Texas A&M University. Primary endpoint: Prediction of type of vaccine administered up to 4 weeks. Started Feb 2022; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccinesalmonella typhi capsular polysaccharide vaccine
Beyond the preview
Go deeper on NCT05346302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346302.